Screening and Characterization of Drugs That Protect Corneal Endothelial Cells Against Unfolded Protein Response and Oxidative Stress

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation

Published Version
doi:10.1167/iovs.16-20147

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:31731702

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Screening and Characterization of Drugs That Protect Corneal Endothelial Cells Against Unfolded Protein Response and Oxidative Stress

Eun Chul Kim,1,2 Tetsuya Toyono,1,3 Cynthia A. Berlinicke,1 Donald J. Zack,1,4 Ula Jurkunas,5 Tomohiko Usui,3 and Albert S. Jun1

Correspondence: Albert S. Jun, Wilmer Eye Institute, Johns Hopkins Medical Institutions, 600 N. Broadway, Wilmer-Woods 376, Baltimore, MD 21287, USA; aljun@jhmi.edu.

ECK and TT contributed equally to the work presented here and should therefore be regarded as equivalent authors.

Submitted: June 18, 2016
Accepted: January 2, 2017

Citation: Kim EC, Toyono T, Berlinicke CA, et al. Screening and characterization of drugs that protect corneal endothelial cells against unfolded protein response and oxidative stress. Invest Ophthalmol Vis Sci. 2017;58:892–900. DOI:10.1167/iovs.16-20147

PURPOSE. To screen for and characterize compounds that protect corneal endothelial cells against unfolded protein response (UPR) and oxidative stress.

METHODS. Bovine corneal endothelial cells (BCECs) were treated for 48 hours with 640 compounds from a Food and Drug Administration (FDA)-approved drug library and then challenged with thapsigargin or H2O2 to induce UPR or oxidative stress, respectively. Cell viability was measured using the CellTiter-Glo survival assay. Selected “hits” were subjected to further dose-response testing, and their ability to modulate expression of UPR and oxidative stress markers was assessed by RT-PCR, Western blot, and measurement of protein carbonyl and 8-hydroxydeoxyguanosine (8-OHdG) adducts in immortalized human corneal endothelial cells (iHCECs).

RESULTS. Forty-one drugs at 20 μM and 55 drugs at 100 μM increased survival of H2O2-challenged cells, and 8 drugs at 20 μM and 2 drugs at 100 μM increased survival of thapsigargin-challenged cells, compared with untreated control cells. Nicergoline, ergothioneine, nimesulide, oxotremorine, and mefenamic acid increased survival of both H2O2- and thapsigargin-challenged cells. Oxotremorine altered DNA damage inducible 3 (CHOP) gene expression, glucose-regulated protein 78 kDa (GRP78) and activating transcription factor 4 (ATF4) protein expression, and protein carbonyl and 8-OHdG levels. Mefenamic acid altered GRP78 protein expression and protein carbonyl and 8-OHdG levels.

CONCLUSIONS. Oxotremorine and mefenamic acid are potential survival factors for corneal endothelial cells under UPR and oxidative stress. The described assay can be further expanded to screen additional drugs for potential therapeutic effect in corneal endothelial diseases such as Fuchs’ endothelial corneal dystrophy.

Keywords: drug screening, corneal endothelial cells, unfolded protein response, oxidative stress, Fuchs’ endothelial corneal dystrophy

Fuchs’ endothelial corneal dystrophy (FECD) is a common cause of corneal vision loss characterized by corneal endothelial (CE) cell loss and abnormalities in Descemet membrane.1–3 Early disease stages are asymptomatic, but in the disease course corneal edema and loss of vision occur approximately 20 years after onset.4 Fuchs’ endothelial corneal dystrophy is among the leading causes of primary corneal transplant surgery in Europe and the United States, and so far there is no definitive conservative (nonsurgical) treatment.5 Evidence of oxidative stress in the pathogenesis of FECD has been described.5–7 Unfolded protein response (UPR) activation leads to endothelial cell apoptosis in Fuchs’ dystrophy and may play a central pathogenic role in this disease.8,9 Koh and Waschek10 have described the survival effects of vasoactive intestinal peptide for cultured corneal endothelial cells undergoing oxidative stress with H2O2. High-throughput screening (HTS) is being used more commonly to identify novel therapeutic compounds.11 Given the previous evidence for endoplasmic reticulum (ER) and oxidative stress in the pathogenesis of FECD, we sought to develop an efficient system to screen a commercially available drug library of Food and Drug Administration (FDA)-approved drugs for improved survival of cultured corneal endothelial cells undergoing ER and oxidative stress. Positive drugs were further tested for dose-response effects and alterations in ER and oxidative stress specific markers.

The approach described in the present work identified mefenamic acid as a drug with positive and specific survival effects against ER and oxidative stress in cultured corneal endothelial cells. This method could be extended to identify drugs with similar effects on known or yet to be elucidated pathophysiologic mechanisms in corneal endothelial diseases.
The overall purpose of this study was to apply a rational approach to drug discovery/screening, which could yield additional agents with the potential to alter the disease course and form the basis of nonsurgical treatments for these disorders.

METHODS

Cell Culture

Primary cultures of bovine corneal endothelial cells (BCECs) from freshly enucleated globes were established by scraping Descemet membrane of excised corneas with a surgical blade and resuspending cells in Dulbecco’s modification of Eagle’s minimum essential medium (DMEM; Cellgro, Manassas, VA, USA) supplemented with 10% fetal calf serum, antibiotic/antimycotic solution (10,000 units of penicillin [base], 10,000 µg of streptomycin [base], and 25 µg of amphotericin B/ml; Invitrogen, Grand Island, NY, USA) and 50 µg/ml of gentamicin (Invitrogen). Cells were maintained at 37°C with 5% CO2 in air on a 6-well plate (Cytoone, Orlando, FL, USA). Once confluence was reached (usually 7–10 days), the primary cultures were subcultured to 96-well plates (Cytoone) in the same medium.

Immortalized human corneal endothelial cell line (iHCECs) was kindly provided by Ula Jurkunas, MD (Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USA). Cells were grown in OptiMEM-I (Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 8% fetal calf serum, antibiotic/antimycotic solution (10,000 units of penicillin [base], 10,000 µg of streptomycin [base], and 25 µg of amphotericin B/ml; Invitrogen), 50 µg/ml of gentamicin (Invitrogen), 5 ng/ml epidermal growth factor (EGF; Sigma-Aldrich Corp., St. Louis, MO, USA), 20 ng/ml of nerve growth factor (NGF; Alfa Aesar, Haverhill, MA, USA), 100 µg of pituitary extract (Alfa Aesar), 20 µg/ml of ascorbic acid (Sigma-Aldrich Corp.), 200 µg/ml of calcium chloride (Sigma-Aldrich Corp.), and 0.08% of chondroitin sulfate (Sigma-Aldrich Corp.). Cells were maintained at 37°C with 5% CO2 in air on a 6-well plate and subcultured every 2 days. Once confluence was reached, iHCECs were subcultured to 96-well plates (Cytoone) in the same medium.

Cytotoxic Assay With H2O2 and Thapsigargin

At 48-hours post-seeding BCECs and iHCECs in triplicate 96-well plates, cells were treated with 100-µl medium containing thapsigargin (0, 6, 10, 20, 30, 50, and 100 µM for BCECs; 0, 2.5, 5.0, 7.5, 10.0, 12.5, 15.0, 17.5, 20.0, 25.0, and 30.0 µM. BCECs; Sigma-Aldrich Corp.) for 24 hours or H2O2 (0, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, and 0.9 mM for BCECs; 0, 0.1, 0.125, 0.15, 0.175, 0.2, 0.225, 0.25, 0.30, and 0.35 mM for iHCECs; Thermo Fisher Scientific) for 4 hours at 37°C in a humidified 5% CO2 atmosphere. Thapsigargin was initially resuspended in dimethyl sulfoxide (DMSO; Sigma-Aldrich Corp.) at a stock concentration of 10 mM. Lethal dose (LD50) values of both thapsigargin and H2O2 were determined by calculating mean cell viability (see below) of triplicate wells relative to untreated cells.

Compound Library

Bovine corneal endothelial cells were used in these experiments. A commercially available FDA-approved drug library was obtained (Enzo Life Science, Inc., Farmingdale, NY, USA) consisting of 640 drugs and bioactive compounds. All drugs were dissolved in 100% DMSO at 10 mM concentration and all have known biological activity. Each drug was tested in triplicate at a 1:100 dilution (100 µM with 1% DMSO) or a 1:500 dilution (20 µM with 0.2% DMSO) in cell culture medium. DMSO-treated control cells were tested in triplicate at 1% or 0.2% DMSO in cell culture medium. After pretreatment with drug for 48 hours, medium in all wells was replaced with thapsigargin (25 µM) in fresh medium for 24 hours or H2O2 (0.6 mM) in fresh medium for 4 hours at 37°C in a humidified 5% CO2 atmosphere. For the compound library screening and all subsequent experiments, drugs tested were dissolved in DMSO. Thus, no drug-treated control cells were incubated in equivalent concentrations of DMSO as experimental cells to avoid artifactitious results from effect of the drug vehicle.

Luminescence Assay

Bovine corneal endothelial cells were used in these experiments. At the end of incubation with drug and toxin (thapsigargin or H2O2), cell viability was determined by adding to each well 100 µl of CellTiter-Glo luminescent reagent (Promega, Madison, WI, USA), which produces light in direct proportion to the amount of ATP and viable cells present. Luminescence was measured in relative light units using a FLUO star OPTIMA luminometer (Optima, Tokyo, Japan). Drugs associated with increased luminescence (cell survival) compared with no drug-treated controls exposed to H2O2 and thapsigargin were selected for further study. Results were calculated as mean luminescence of treated replicates/mean luminescence of control replicates ×100. Control replicates were cultured in cell culture medium without H2O2, thapsigargin, or other additional agents. Level of cell protection for each agent (proportion of increased cell survival) against oxidative stress or UPR was assessed as grade 0 (no protection), less than 5%; grade 1 (low protection), 5% to 24%; grade 2 (medium protection), 25% to 44%; grade 3 (high protection), 45% to 69%; grade 4 (very high protection), 70% or more compared with cells with H2O2 or thapsigargin and no additional agent.

Dose Response Assays

After initial selection of drugs with medium to high levels of protection (grade 2–3), additional dose response assays were performed with BCECs to determine the effective dose range for each protective drug and to determine the efficacy of an optimal dose of drug against oxidative stress and UPR. The following drugs were tested (all from Sigma-Aldrich Corp.): oxtremorine, mefenamic acid, nimesulide, and diclofenac. Each drug was resuspended in DMSO at a stock concentration of 10 mM and diluted in cell culture medium. Oxtremorine, mefenamic acid, and nimesulide were retested in quadruplicate at 0.0, 0.5, 1.0, 3.0, 10.0, 30.0, and 60.0 (oxotremorine and mefenamic acid only), and 100-µM (nimesulide only) concentrations for both H2O2 and thapsigargin. Diclofenac was tested in quadruplicate at 0.0, 0.05, 0.1, 0.2, 0.3, and 1.0 µM concentrations for H2O2 and 0.0, 0.3, 1.0, 3.0, 10.0, 30.0, 60.0 (oxotremorine and mefenamic acid only), and 100-µM (nimesulide only) concentrations for both H2O2 and thapsigargin. Dose response assays were performed under the same H2O2 or thapsigargin conditions as used above in the compound library screening. Negative control cells with no drug treatment and no H2O2 or thapsigargin conditioning were also included to determine baseline cell viability (luminescence). Relative cell viability (%) for each drug and concentration was calculated as mean luminescence in H2O2 or thapsigargin conditioned cells/mean luminescence in negative controls ×100.

Additionally, iHCECs were used to confirm the effectiveness of oxtremorine and mefenamic acid. Oxtremorine was tested in quadruplicate at 0.0-, 10.0-, and 60.0-µM concentrations.
for H₂O₂ (0.18 mM) and 0.0- and 200.0-μM concentrations for thapsigargin (27.5 μM). Mefenamic acid was tested in quadruplicate at 0.0- and 30.0-μM concentrations for H₂O₂ (0.18 mM) and 0.0- and 20.0-μM concentrations for thapsigargin (27.5 μM).

**Real-Time PCR**

Immortalized HCECs cultured in triplicate 6-well plates were pretreated with 50.0-μM oxotremorine, 20.0-μM mefenamic acid, or no drug (only 0.5% and 0.2% DMSO, respectively) for 48 hours followed by treatment with thapsigargin (2.5 μM) for 24 hours at 37°C in a humidified 5% CO₂ atmosphere. RNA samples were extracted from hHCECs with TRIzol (Ambion, Austin, TX, USA) using the RNaseasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. A 100-ng quantity of RNA was reverse transcribed using a High Capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, CA, USA). Real-time PCR was performed using the TaqMan Gene Expression Master Mix (2%; Applied Biosystems), preamplified cDNA products (diluted 1:20; 5 μL), TaqMan Gene Expression Master Mix (2 μL), and human-specific primers (Supplement Table S1; Applied Biosystems) in a 20-μL reaction volume. A no-template control was included in each experiment to confirm the absence of DNA contamination. All assays used similar amplification efficiency, and a ΔCt experimental design was used for relative quantification. Data analysis was performed with StepOne software (Version 2.2; Applied Biosystems). Data were normalized to GAPDH and are expressed as relative expression compared with cells untreated with thapsigargin, oxotremorine, or mefenamic acid.

**Western Blot**

Immortalized HCECs cultured in triplicate 6-well plates were pretreated with 50.0-μM oxotremorine, 20.0-μM mefenamic acid, or no drug for 48 hours followed by treatment with thapsigargin (2.5 μM) for 24 hours at 37°C in a humidified 5% CO₂ atmosphere. Cells were lysed with ice-cold Tissue Protein Extraction Reagent (Thermo Fisher Scientific) containing protease inhibitor (1%) and EDTA (1%). Total protein concentration was measured using a protein assay kit (Thermo Fisher Scientific) and each sample was adjusted to 20 μg/mL. Proteins were subjected to SDS-PAGE (Mini-PROTEAN TGX Gels; Bio-Rad, Hercules, CA, USA) and transferred to polyvinylidene fluoride membranes (The PerfectMembrane; GenHunter Corporation, Nashville, TN, USA) that had been soaked in methanol for 1 minute. After blocking with 5% milk for 1 hour, the membranes were then incubated overnight with rabbit anti-ATF4 antibody (1:1000 dilution; Cell Signaling Technology, Danvers, MA, USA), or rabbit anti-GRP78 antibody (1:1000; Cell Signaling Technology). The membranes were then incubated with horseradish peroxidase-conjugated donkey anti-rabbit IgG antibodies (1:10,000 dilution; Cell Signaling Technology) for 30 minutes. The membrane was washed with tris buffered saline with Tween 20 (TBST; Cell Signaling Technology) and antigen was detected using ECL solution (Pierce Biotechnology, Inc., Rockford, IL, USA). Membranes were stripped with Restore Western blotting stripping buffer (Thermo Fisher Scientific) using manufacturer’s instructions, reblocked with 5% milk for 1 hour, and re stained for GAPDH using rabbit anti-GAPDH antibody (HRP conjugate, 1:10000; Cell Signaling Technology) with 1-hour incubation at room temperature.

**ELISA of Oxidative Stress Markers**

Immortalized HCECs cultured in triplicate 6-well plates were pretreated with 50.0-μM oxotremorine, 20.0-μM mefenamic acid, or no drug for 48 hours followed by treatment with H₂O₂ (0.8 mM) for 4 hours at 37°C in a humidified 5% CO₂ atmosphere. Protein carbonyls and 8-hydroxydeoxyguanosine (8-OHdG) were evaluated as oxidative stress markers. Protein carbonyls in hHCECs were measured using ELISA (OxiSelect Protein Carbonyl ELISA Kit; Cell Biolabs, San Diego, CA, USA) according to the manufacturer’s protocols. Treated cells were lysed with ice-cold Tissue Protein Extraction Reagent (Thermo Fisher Scientific) containing protease inhibitor (1%) and EDTA (1%). Total protein concentration was measured using a protein assay kit (Thermo Fisher Scientific) and each sample was diluted to 10 μg/mL. 8-OHdG in iHCECs was measured by DNA extraction (QIAamp DNA Mini Kit; Qiagen) followed by ELISA (OxiSelect Oxidative DNA Damage ELISA Kit; Cell Biolabs).

**Statistical Analysis**

Statistical analysis was performed with two-tailed Student’s t-test using SPSS (version 16.0; IBM, Armonk, NY, USA) or JMP (version 10.0.2; SAS, Cary, NC, USA) and P less than 0.05 was considered statistically significant.

**RESULTS**

**Preliminary Cytotoxic Assay**

Cytotoxic effects of BCECs exposed to H₂O₂ for 4 hours and thapsigargin for 24 hours showed a dose-dependent response. The LD₅₀ values for H₂O₂ and thapsigargin against BCECs were 0.6 mM and 25.6 μM, respectively (Supplementary Figs. S1A, S1B). In a similar way, the LD₅₀s for H₂O₂ and thapsigargin against iHCECs were 0.18 mM and 16.5 μM (data not shown).
Initial Screen

Bovine corneal endothelial cells were used in this screening test. For a flow chart of the initial screening process (Fig. 1). Initial screening of the 640 drug library using conditions established by the preliminary cytotoxic assay demonstrated 55 drugs at 100 μM and 41 at 20 μM with moderate to high levels of increased cell survival (grade 2–3) against H2O2 conditioning. Against thapsigargin conditioning, two drugs at 100 μM and eight at 20 μM demonstrated moderate to high levels of increased cell survival. Overall, 14 drugs demonstrated increased cell survival with both concentrations of drug tested showing a grade 2 to 3 effect against either oxidative stress or UPR (Supplementary Table S2). Five drugs (ergothioneine, nicergoline, nimesulide, mefenamic acid, and oxotremorine) were found to demonstrate a grade 2 to 3 survival effect at one concentration against both oxidative stress and UPR (Supplementary Table S2).

Dose Response Assays

After initial screening of the FDA drug library, dose-response assays with BCECs were performed for the five compounds with survival effects against both oxidative stress and UPR. Nicergoline and ergothioneine did not exhibit a clear response (data not shown), but oxotremorine, mefenamic acid, and nimesulide exhibited a significant dose response. Cell viability of 0.3 (75.2 ± 14.1%, P = 0.0022), 1.0 (80.8 ± 4.0%, P = 0.00001), 3.0 (81.4 ± 6.7%, P = 0.00005), 10.0 (82.5 ± 5.0%, P = 0.00003), 30.0 (76.2 ± 4.7%, P = 0.00004), and 60.0 μM (75.4 ± 3.6%, P = 0.00002) oxotremorine-treated cells against oxidative stress was significantly increased compared with 0.0-μM control (43.3 ± 5.1%; Fig. 2A). Cell viability of 0.3 (74.8 ± 6.7%, P = 0.01), 1.0 (75.6 ± 8.0%, P = 0.02), 3.0 (77.1 ± 7.6%, P = 0.02), and 10.0 μM (80.2 ± 11.0%, P = 0.01) oxotremorine-treated cells against UPR was significantly increased compared with 0.0-μM control (66.3 ± 3.1%; Fig. 2B). Overall, oxotremorine demonstrated a maximal effect at 10.0 μM of 90.5% increased cell viability against H2O2 and a maximal effect at 10.0 μM of 21.0% increased cell viability against thapsigargin.

Cell viability of 0.3 (69.1 ± 2.0%, P = 0.02), 1.0 (71.2 ± 8.2%, P = 0.01), 3.0 (73.6 ± 8.7%, P = 0.01), 10.0 (73.2 ± 3.5%, P = 0.005), and 30.0 μM (68.7 ± 3.4%, P = 0.03) mefenamic acid-treated cells against oxidative stress was significantly increased compared with 0.0-μM control (60.8 ± 6.0%; Fig. 3A). Cell viability of 10.0 (57.4 ± 2.4%, P = 0.04) and 30.0 μM (61.7 ± 3.1%, P = 0.04) mefenamic acid-treated cells against UPR was significantly increased compared with 0.0-μM control (51.9 ± 3.7%; Fig. 3B). Overall, mefenamic acid demonstrated a maximal effect at 3.0 μM of 21.1% increased cell viability against H2O2 and a maximal effect at 30.0 μM of 18.9% increased cell viability against thapsigargin.

Cell viability of 1.0 (47.0 ± 3.5%, P = 0.01) and 3.0 μM (51.3 ± 3.8%, P = 0.001) nimesulide-treated cells against oxidative stress was significantly increased compared with 0.0-μM control (41.9 ± 1.5%; Fig. 4A). Cell viability of 1.0 (57.0 ±
4.6%, $P = 0.04$) and 3.0 $\mu$M (61.0 ± 5.4%, $P = 0.01$) nimesulide-treated cells against UPR was significantly increased compared with 0.0 $\mu$M control (50.8 ± 3.8%; Fig. 4B). Overall, nimesulide showed a maximal effect at 3.0 $\mu$M of 22.4% increased cell viability against H$_2$O$_2$ and 20.1% increased cell viability against thapsigargin.

Based on the above results indicating a protective effect of the nonsteroidal anti-inflammatory drugs (NSAIDs) mefenamic acid and nimesulide on BCECs exposed to oxidative stress and UPR, we selected diclofenac, a highly potent NSAID13 for additional dose-response testing. Cell viability of 0.3- (60.1 ± 5.2%, $P = 0.04$) and 3.0- (50.6 ± 4.6%, $P = 0.005$) diclofenac-treated cells against oxidative stress was significantly increased compared with 0.0- $\mu$M control (52.1 ± 2.7%; Fig. 5A). However, cell viability of 3.0- (51.5 ± 3.4%, $P = 0.01$), 10.0- (50.6 ± 4.6%, $P = 0.02$), 30.0- (50.0 ± 4.7%, $P = 0.01$), 100.0- (45.2 ± 2.9%, $P = 0.0005$), and 300.0- $\mu$M (43.4 ± 4.2%, $P = 0.0007$) diclofenac-treated cells against UPR was significantly decreased compared with 0.0- $\mu$M control (57.8 ± 3.1%; Fig. 5B). Overall diclofenac demonstrated a maximal effect at 1.0 $\mu$M of 18.2% increased cell viability against H$_2$O$_2$ and a maximal effect at 300 $\mu$M of 24.9% decreased cell viability against thapsigargin.

In addition, we sought to characterize potential cell protective effects of oxotremorine and mefenamic acid on HCECs using iHCECs. Cell viability of 60.0- $\mu$M (78.4 ± 7.3%, $P = 0.0002$) oxotremorine-treated cells against oxidative stress was significantly increased compared with 0.0- $\mu$M control (40.9 ± 6.3%; Fig. 6A). Cell viability of 200.0- $\mu$M (78.4 ± 15.4%, $P = 0.05$) oxotremorine-treated cells against UPR was significantly increased compared with 0.0- $\mu$M control (37.5 ± 4.5%; Fig. 6B). Cell viability of 30.0- $\mu$M (89.2 ± 5.1%, $P = 0.004$) mefenamic acid–treated cells against oxidative stress was significantly increased compared with 0.0- $\mu$M control (46.1 ± 7.1%; Fig. 6C). Cell viability of 20.0- $\mu$M (79.0 ± 11.0%, $P = 0.009$) mefenamic acid–treated cells against UPR was significantly increased compared to 0.0- $\mu$M control (37.6 ± 6.3%; Fig. 6D).

**Effects of Oxotremorine and Mefenamic Acid on UPR Markers**

To assess mRNA level effects of oxotremorine and mefenamic acid on UPR markers in HCECs, iHCECs were pretreated with 50.0- $\mu$M oxotremorine or 20.0- $\mu$M mefenamic acid, exposed to thapsigargin, and real-time PCR was performed for $ATF4$ and $CHOP$ (Supplementary Table S1), two commonly used markers of UPR.14,15 For thapsigargin-exposed iHCECs, oxotremorine treatment showed a trend for reduced $ATF4$ mRNA expression to 118.2 ± 43.7% ($P = 0.23$) compared with untreated controls (148.3 ± 28.3%) and reduced $CHOP$ mRNA expression to 112.3 ± 60.6% ($P = 0.024$) compared with untreated controls (188.1 ± 8.0%; Fig. 7A). For thapsigargin-exposed iHCECs, mefenamic acid treatment showed trends for reduced $ATF4$ mRNA expression to 117.0 ± 13.6% ($P = 0.10$) compared with untreated controls (135.6 ± 18.1%) and reduced $CHOP$ mRNA expression to 170.9 ± 19.7% ($P = 0.06$) compared with untreated controls (190.9 ± 6.5%; Fig. 7B).

To assess protein level effects of oxotremorine and mefenamic acid on UPR markers in HCECs, iHCECs were pretreated with 50.0- $\mu$M oxotremorine or 20.0- $\mu$M mefenamic acid and nimesulide treatment showed trends for reduced $ATF4$ protein expression to 117.0 ± 13.6% ($P = 0.10$) compared with untreated controls (135.6 ± 18.1%) and reduced $CHOP$ protein expression to 170.9 ± 19.7% ($P = 0.06$) compared with untreated controls (190.9 ± 6.5%; Fig. 7B).

**Figure 4.** Cell viability of nimesulide-treated bovine corneal endothelial cells after H$_2$O$_2$ (A) or thapsigargin- (B) induced stress. Results are expressed as mean ± SD. *$P < 0.05$.

**Figure 5.** Cell viability of diclofenac-treated bovine corneal endothelial cells after H$_2$O$_2$ (A) or thapsigargin- (B) induced stress. Results are expressed as mean ± SD. *$P < 0.05$. 
acid, exposed to thapsigargin, and Western blot was performed for ATF4 and GRP78, which are also commonly used markers of UPR. For thapsigargin-exposed iHCECs, oxotremorine treatment increased GRP78 protein expression to 89.46 ± 12.37% (P = 0.013) compared with untreated controls (46.26 ± 12.19%) and decreased ATF4 protein expression to 39.43 ± 30.77% (P = 0.039) compared with untreated controls 64.65 ± 141.3% (Fig. 8A). For thapsigargin-exposed iHCECs, mefenamic acid treatment increased GRP78 protein expression to 45.5 ± 15.49% (P = 0.038) compared with untreated controls (16.8 ± 52.7%) and showed a trend for decreased ATF4 protein expression to 193.54 ± 106.97% (P = 0.44) compared with untreated controls (270.61 ± 1113.52%; Fig. 8B).

Effects of Oxotremorine and Mefenamic Acid on Oxidative Stress Markers

To assess effects of oxotremorine and mefenamic acid on oxidative stress in HCECs, iHCECs were pretreated with 50.0-μM oxotremorine or 20.0-μM mefenamic acid, exposed to H2O2, and protein carbonyl and 8-OHdG levels were measured by ELISA. For H2O2-exposed iHCECs, mefenamic acid treatment reduced protein carbonyl levels to 90.7 ± 7.1% (P = 0.037), and oxotremorine treatment reduced protein carbonyl levels to 83.8 ± 10.7% (P = 0.028) compared with untreated controls (131.5 ± 21.9%; Fig. 9A). For H2O2-exposed iHCECs, mefenamic acid treatment reduced 8-OHdG levels to 173.3 ± 15.7% (P = 0.0008), and oxotremorine treatment reduced 8-OHdG levels to 175.0 ± 31.2% (P = 0.0051) compared with untreated controls (275.0 ± 21.2%; Fig. 9B).

DISCUSSION

Fuchs’ endothelial corneal dystrophy results from primary loss of corneal endothelial cells and is a common cause of corneal vision loss. Current definitive therapy includes endothelial keratoplasty, and there is no nonsurgical treatment to delay or prevent disease progression. Multiple studies using keratoplasty tissue have shown evidence of oxidative stress in FECD. We have shown evidence of unfolded protein response activation in FECD patient corneas and in a mouse model of FECD. Thus, we sought to develop a system to screen for drugs with corneal endothelial cell survival effects against oxidative stress and UPR. The link between oxidative stress and UPR has been established in multiple reports. Holtz et al.
described oxidative stress-triggered UPR in cell death evoked by Parkinson mimetics. Tumor necrosis factor-alpha has been shown to induce UPR in a reactive oxygen species (ROS) dependent fashion.\textsuperscript{17} Tagawa et al.\textsuperscript{18} demonstrated endoplasmic reticulum (ER) stress–mediated apoptosis is induced by cigarette smoke via an ROS-dependent mechanism.\textsuperscript{19} Our results demonstrate a dose response effect of the muscarinic receptor agonist, oxotremorine, and the NSAIDs, mefenamic acid and nimesulide, against oxidative stress and UPR in a BCEC culture model. Although bovine cells are commonly used in studies of the corneal endothelium,\textsuperscript{20–22} their use is a potential shortcoming of our system. However, our previous experience with primary cultured human corneal endothelium\textsuperscript{23–25} indicated potential difficulties obtaining adequate numbers of phenotypically consistent cells for the high throughput scale of these experiments. Thus, we used immortalized corneal endothelial cells\textsuperscript{12} to confirm dose-responsive survival and further characterize the effects of oxotremorine and mefenamic acid against ER and oxidative stress in human cells. Another potential shortcoming of our system is the use of pretreatment with pharmacologic agents prior to the application of cellular stress. We chose this design expecting it to maximize effects on cell survival. However, clinical situations would likely include the possibility of initiating drug therapy in patients with moderate to advanced disease (i.e., after intermediate to severe levels of cell stress were already established). Thus, follow-up studies in cultured HCECs with pre- and post-stress application of candidate drugs are warranted prior to drawing further implications in diseases such as FECD. A further shortcoming of our work involves short-term responses to relatively high doses of cytotoxic agents. Such a model, though convenient for high throughput analysis, may have limited relevance to FECD, which more likely involves lower levels of chronic cellular stress.

Stimulation of muscarinic receptors provides substantial protection from DNA damage, oxidative stress, and mitochondrial impairment.\textsuperscript{26} Oxotremorine prevents camptothecin-induced mitochondrial cytochrome c release, Bcl-2 depletion, and Bax accumulation.\textsuperscript{26} In addition, activation of muscarinic receptors blocks caspase 3 activation.\textsuperscript{27} The mechanism by which oxotremorine increases survival of cultured corneal endothelial cells treated with the UPR inducer, thapsigargin, is not well understood. Thapsigargin blocks the ability of the cell to pump calcium into the ER, which results in ER damage.\textsuperscript{28} Oxotremorine has also been shown to cause an increase in intracellular free Ca\textsuperscript{2+}.\textsuperscript{29} Thus, one could speculate that oxotremorine would synergize with thapsigargin to cause increased cytotoxicity mediated by intracellular calcium levels. This result was not observed in our cell survival data for reasons yet to be elucidated.

Mefenamic acid decreases production of the free radical nitric oxide and reduces cytochrome c release from mitochondria induced by A\textsubscript{B}1-42, Swe-APP, or APP-CTs in neuronal cells.\textsuperscript{30} Similarly, our results show significantly decreased oxidative stress markers in mefenamic acid-treated iHCECs exposed to H\textsubscript{2}O\textsubscript{2}. Thus, our results indicate, for the first time to our knowledge, the ability of mefenamic acid to upregulate the UPR marker GRP78 and to alleviate cytotoxicity caused by the UPR inducer, thapsigargin.

COX-2 inhibitors such as nimesulide act as antioxidants to correct lipid peroxidation products such as malondialdehyde (MDA).\textsuperscript{31} Unfolded protein response due either to expression
of viral surface proteins or drugs can stimulate the expression of COX-2 through the nuclear factor kappa-B and pp38 kinase pathways. Thus, NSAIDs may represent an attractive agent to reduce both oxidative stress and UPR in corneal cells in vivo. Additional NSAIDs in our drug library showed a partial protective effect against either H2O2 (celexcoxib, diclofenac, fenoprofen, ketoprofen, niflumic acid, piroxicam, and tolfe-namic acid) or thapsigargin (aceclofenac). Diclofenac was selected as a potent NSAID for additional follow-up studies in our ER and oxidative stress model system. Our results indicate positive cell survival effects against oxidative stress, but decreased survival against UPR (Fig. 5). Diclofenac previously has been shown to reduce superoxide and peroxide production as well as to reduce glutathione depletion in human lens epithelial cells exposed to oxidative stress. However, diclofenac also activates the PERR pathway of the UPR, which induces the expression of the proapoptotic GADD153/CHOP. Thus, our results indicate differential effects of individual NSAIDs on the responses to ER versus oxidative stress in corneal endothelial cells.

Chiu et al. recently used a high throughput assay system and elegant mechanistic studies to identify the NSAIc, glafenine, as being able to reduce retention of SLC4A11 mutant protein in the ER and increase post-ER trafficking to the cell membrane. Properly trafficked mutant SLC4A11 was further shown to retain partial function. These authors suggested that prostaglandin synthesis may contribute to ER and oxidative stress-triggered unfolded protein response (UPR) counteracts ROS accumulation by TNFalpha. Further, diclofenac supports positive cell survival against oxidative stress. Based on our results, it is tempting to speculate that NSAIDs such as mefenamic acid, nimesulide, or others may have potential efficacy as a survival factor for corneal endothelial cells under these stressors in vivo. Our screening system also could be used as the basis of an expanded approach to identify additional therapeutic targets for corneal endothelial diseases.

Acknowledgments
Supported by grants from the J. Willard and Alice S. Marriott Foundation (Bethesda, MD, USA), Margaret Andrews, Edward Colburn, Lorraine Collins, Richard Dianich, Mary Finegan, Barbara and Peter Freeman, Stanley Friedler, MD, Ida Jeffries, Herbert Kasoff, Diane Kemker, Jean Mattison, Florenz Ourisman, Lee Silverman, Norman Tunkel, PhD, the National Eye Institute ET 019874 (all to AS; Bethesda, MD, USA), Japan Eye Bank Association (Tokyo, Japan) and EBAA Richard Lindstrom Research Grant (TT; Washington, DC, USA), and generous support from the Guerrieri Family Foundation (Salisbury, MD, USA).

Disclosure: E.C. Kim, None; T. Toyono, None; C.A. Berlinicke, None; D.J. Zack, None; U. Jurkunas, None; T. Uesl, None; A.S. Jun, None

References


